A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.
about
LNCaP Atlas: gene expression associated with in vivo progression to castration-recurrent prostate cancerAndrogen-regulated genes differentially modulated by the androgen receptor coactivator L-dopa decarboxylase in human prostate cancer cellsMale germ cell-associated kinase is overexpressed in prostate cancer cells and causes mitotic defects via deregulation of APC/CCDH1Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptorLeupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cellsLEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasionA novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancerElectrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifsMelanoma antigen gene protein MAGE-11 regulates androgen receptor function by modulating the interdomain interactionAndrogen receptor molecular biology and potential targets in prostate cancerHormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancerEpidermal-growth-factor-dependent phosphorylation and ubiquitinylation of MAGE-11 regulates its interaction with the androgen receptorStat3 enhances transactivation of steroid hormone receptorsStable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cellsRecognition and accommodation at the androgen receptor coactivator binding interfaceThe roles of sex steroid receptor coregulators in cancerA sting in the tail: the N-terminal domain of the androgen receptor as a drug targetOncolytic adenovirus-mediated therapy for prostate cancerChemotherapy and its evolving role in the management of advanced prostate cancerTargeting the adaptive molecular landscape of castration-resistant prostate cancerModulation of Androgen Receptor Activation Function 2 by Testosterone and DihydrotestosteroneTargeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.A multiscale, mechanism-driven, dynamic model for the effects of 5α-reductase inhibition on prostate maintenanceAndrogen signaling promotes translation of TMEFF2 in prostate cancer cells via phosphorylation of the α subunit of the translation initiation factor 2Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptorPterostilbene-isothiocyanate conjugate suppresses growth of prostate cancer cells irrespective of androgen receptor statusPerturbing the cellular levels of steroid receptor coactivator-2 impairs murine endometrial function.Cofactor of BRCA1 modulates androgen-dependent transcription and alternative splicing.A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental dataBeta-catenin binds to the activation function 2 region of the androgen receptor and modulates the effects of the N-terminal domain and TIF2 on ligand-dependent transcriptionA role for the androgen-receptor in clinically localized and advanced prostate cancer.ERK regulates calpain 2-induced androgen receptor proteolysis in CWR22 relapsed prostate tumor cell linesTACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancerOptimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.Functionality of androgen receptor-based gene expression imaging in hormone refractory prostate cancerMutation of the androgen receptor causes oncogenic transformation of the prostateThe nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancerAndrographolide targets androgen receptor pathway in castration-resistant prostate cancer.Normal and cancer-related functions of the p160 steroid receptor co-activator (SRC) family
P2860
Q21202034-09F1AAEF-B53C-4130-B05A-321376ECEADAQ21245730-90DD6A95-540A-4FB7-B8E6-11A9FFB3BDD7Q24292955-2F673D50-4268-4118-96AB-BD1F4B9DFE6FQ24306066-BA702B8C-F5CE-42BC-9C67-06E5CEADF3B6Q24308733-D39DCCAC-B260-4B19-8157-0FA90A7A41EDQ24313620-C6F325DC-E213-4B56-A51B-D53A8D323C2CQ24338270-BDFEEC9F-9CFF-4B88-869E-DF523B314BF3Q24550576-CB0886B1-77AC-4F3B-BD07-ABF084D0B4CBQ24556963-C78F29C5-5399-47B2-A92C-0EE545A195BAQ24602861-3BBBEE25-D5B1-4D83-A230-30136548D1C1Q24646000-529839BE-E229-43F0-93F1-E6A28AB9124DQ24652929-937C6A4E-855D-434E-A816-07A364744AD2Q24792987-CBFE6742-59A7-49BD-8ADF-8BAA49C19D76Q24795887-58888040-459F-406D-A040-3C42AF5A6F15Q24799399-F0FBDBE8-F77F-4D5C-BF90-6C562BC786D4Q24799904-D10DFBE1-F06D-4BB6-B822-9C5BA2896EE7Q26747094-1F811C6D-662B-44D9-9B20-62ACEFA9DD3DQ27004796-2DE79D59-013B-4143-BBBF-85B528438DB3Q27008883-2C216591-7CBD-4D98-AAC6-95D72CFA6141Q27022821-6534841B-69B4-40D1-95D1-5F67AF0D59B0Q27646416-412CFB00-8E89-4EA9-A064-C376EBD57471Q27675350-C92364A8-3F5D-424D-8471-6F3C4F83D142Q28483635-4D69F44A-27D9-4DAD-A89B-FCCDFE83D84FQ28486024-FCAA4F7B-CB64-4B37-B32B-88AF1872FDEBQ28534575-48C1D4E3-1F15-449F-9E0B-7BD9BDE4D2AEQ28541923-28F1ABD9-1737-46D2-A5C9-32A4136D4251Q30412564-4AADF365-FEE1-4123-A67B-3FDAC88FF453Q30439381-40A87C57-B4BA-4034-ADAC-2EE38EE9B203Q30983127-2BAC0CEC-1E31-4E80-84F1-A3701E4E91ADQ33292178-191A9A47-D945-48A8-B5EA-C61471DE9501Q33561073-BE9B2F3B-3177-4F19-967C-247B30A47165Q33593873-F4CCB3A5-9044-4E33-BC20-678D03FE99FDQ33636574-FCCFC77D-F22D-45A4-9108-239DCE6C3F63Q33647321-4411447B-5AAB-460B-96DF-724DF0E8B5EFQ33650205-66862B64-1AE0-4EB8-AB98-F186325148D3Q33732154-AA05BBFE-ADC6-4182-B57B-2E11A4E6F0A6Q33735295-CF7AD16C-D2C9-43A3-ADB6-BB853304FAC3Q33823702-63F7B572-A6E3-41A6-9639-7B74CEF3FEE9Q33968384-0AE65848-8603-4FF5-A08B-F953FF9B392FQ34013708-E4F0ABCE-1853-4F31-BE01-8934759016F0
P2860
A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
A mechanism for androgen recep ...... androgen deprivation therapy.
@en
A mechanism for androgen recep ...... androgen deprivation therapy.
@nl
type
label
A mechanism for androgen recep ...... androgen deprivation therapy.
@en
A mechanism for androgen recep ...... androgen deprivation therapy.
@nl
prefLabel
A mechanism for androgen recep ...... androgen deprivation therapy.
@en
A mechanism for androgen recep ...... androgen deprivation therapy.
@nl
P2093
P1433
P1476
A mechanism for androgen recep ...... androgen deprivation therapy.
@en
P2093
C W Gregory
E M Wilson
F S French
J L Mohler
R T Johnson
P304
P407
P577
2001-06-01T00:00:00Z